{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,3]],"date-time":"2024-03-03T01:06:15Z","timestamp":1709427975017},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American Journal of Clinical Pathology"],"published-print":{"date-parts":[[2006,5,1]]},"DOI":"10.1309\/abey-v2vk-e6dh-xaaa","type":"journal-article","created":{"date-parts":[[2006,3,30]],"date-time":"2006-03-30T19:28:00Z","timestamp":1143746880000},"page":"665-671","source":"Crossref","is-referenced-by-count":0,"title":["Performance Characteristics of Two Real-Time PCR Assays for the Quantification of Epstein-Barr Virus DNA"],"prefix":"10.1093","volume":"125","author":[{"given":"Charles E.","family":"Hill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shealynn B.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth E.","family":"Culler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James C.","family":"Zimring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick S.","family":"Nolte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela M.","family":"Caliendo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"E00001","unstructured":"Holmes RD, Sokol RJ. Epstein-Barr virus and post-transplant lymphoproliferative disease. Pediatr Transplant. 2002;6:456-464."},{"key":"E00002","unstructured":"Shahinian VB, Muirhead N, Jevnikar AM, et al. Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoproliferative disorder in adult renal allograft recipients. Transplantation. 2003;75:851-856."},{"key":"E00003","unstructured":"Ho M. Risk factors and pathogenesis of posttransplant lymphoproliferative disorders. Transplant Proc. 1995;27(5 suppl 1):38-40."},{"key":"E00004","unstructured":"Ho M, Miller G, Atchison RW, et al. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection. J Infect Dis. 1985;152:876-886."},{"key":"E00005","unstructured":"Muti G, Cantoni S, Oreste P, et al. Post-transplant lymphoproliferative disorders: improved outcome after clinicopathologically tailored treatment. Haematologica. 2002;87:67-77."},{"key":"E00006","unstructured":"Campe H, Jaeger G, Abou-Ajram C, et al. Serial detection of Epstein-Barr virus DNA in sera and peripheral blood leukocyte samples of pediatric renal allograft recipients with persistent mononucleosis-like symptoms defines patients at risk to develop post-transplant lymphoproliferative disease. Pediatr Transplant. 2003;7:46-52."},{"key":"E00007","unstructured":"Gartner BC, Schafer H, Marggraff K, et al. Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease [published correction appears in J Clin Microbiol. 2002;40:2316]. J Clin Microbiol. 2002;40:351-358."},{"key":"E00008","unstructured":"Kogan-Liberman D, Burroughs M, Emre S, et al. The role of quantitative Epstein-Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: a preliminary experience. J Pediatr Gastroenterol Nutr. 2001;33:445-449."},{"key":"E00009","unstructured":"van Esser JW, Niesters HG, van der Holt B, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood. 2002;99:4364-4369."},{"key":"E00010","unstructured":"Wagner HJ, Wessel M, Jabs W, et al. Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction. Transplantation. 2001;72:1012-1019."},{"key":"E00011","unstructured":"Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310."},{"key":"E00012","unstructured":"Stevens SJ, Pronk I, Middeldorp JM. Toward standardization of Epstein-Barr virus DNA load monitoring: unfractionated whole blood as preferred clinical specimen. J Clin Microbiol. 2001;39:1211-1216."},{"key":"E00013","unstructured":"van Esser JW, van der Holt B, Meijer E, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood. 2001;98:972-978."}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"deposited":{"date-parts":[[2015,11,19]],"date-time":"2015-11-19T15:10:45Z","timestamp":1447945845000},"score":1,"resource":{"primary":{"URL":"http:\/\/ajcp.metapress.com\/openurl.asp?genre=article&id=doi:10.1309\/ABEY-V2VK-E6DH-XAAA"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,1]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,5,1]]}},"alternative-id":["ABEYV2VKE6DHXAAA"],"URL":"https:\/\/doi.org\/10.1309\/abey-v2vk-e6dh-xaaa","relation":{},"ISSN":["0002-9173"],"issn-type":[{"value":"0002-9173","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5,1]]}}}